92999-26-3

Basic information

• Product Name: 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-9-(1-hydroxyethyl)-, hydrochloride, (7S-(7-alpha,9-alpha,9(S*)))-
• CAS NO: 92999-26-3
• Molecular Weight: 535.979
• Mol File: 92999-26-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-9-(1-hydroxyethyl)-, hydrochloride, (7S-(7-alpha,9-alpha,9(S*)))-(CAS DataBase Reference)
• NIST Chemistry Reference: 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-9-(1-hydroxyethyl)-, hydrochloride, (7S-(7-alpha,9-alpha,9(S*)))-(92999-26-3)
• EPA Substance Registry System: 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-7-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-6,9,11-trihydroxy-9-(1-hydroxyethyl)-, hydrochloride, (7S-(7-alpha,9-alpha,9(S*)))-(92999-26-3)

Safety Data

• Hazardous Substances Data: 92999-26-3(Hazardous Substances Data)

Upstream product

• 58957-92-9 idarubicin 

Relevant articles and documents

Microbial and Mammalian Stereoselective Conversion of 4-Demethoxydaunorubicin to the Corresponding 13-(R)-Dihydro Derivative

4-Demethoxydaunorubicin (3), a new synthetic antitumor anthracycline under clinical evaluation, was stereoselectively converted to the corresponding 13-(R)-dihydro derivative (4-R) by using a blocked mutant of Streptomyces peucetius.The absolute configuration of the C(13) of the new anthracycline 4-R was assigned on the basis of 1H-NMR examination of the 9,13-O-isopropylidene derivative of its aglycone 5-R in comparison with the corresponding C(13) epimers obtained by chemical reduction.Compound 4-R was also identified as the major human urinary metabolite of 3.